We analyzed approximately 20,000 patients with DM and MAFLD using a large-scale epidemiologic cohort and compared approximately 6,500 well-balanced pairs of new users of SGLT2 or DPP4 inhibitors with propensity score matching. Here, SLC5A2 is linked to diabetes mellitus.